Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy.

Blood - 23 Apr 2009

Li Chun, Schwarz Ute I, Ritchie Marylyn D, Roden Dan M, Stein C Michael, Kurnik Daniel

Abstract excerpt

Genetic variants in CYP2C9 and VKORC1 strongly affect steady-state warfarin dose. However, these variants also affect early international normalized ratio (INR) values during warfarin initiation. We examined whether CYP2C9/VKORC1 genotypes provide information about warfarin sensitivity additional to that provided by early INR responses. In 214 patients starting warfarin with INR-guided dose adjustments, we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aryl Hydrocarbon Hydroxylases
Share to Cytochrome P-450 CYP2C9

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dose-Response Relationship, Drug

Share to International Normalized Ratio

Share to Mixed Function Oxygenases

Share to Substrate Specificity

Share to Vitamin K Epoxide Reductases

Share to Warfarin

Source

Open in PubMed Open full text

Identifiers

PMID: 19074728
DOI: 10.1182/blood-2008-09-176859
PMCID: PMC2673121

Genes

VKORC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy.PMID 19074728Read ↗

Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy.Semantic proximity Read ↗

Genetic determinants of response to warfarin during initial anticoagulation.Semantic proximity Read ↗

Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy.Semantic proximity Read ↗

Genetic testing for warfarin therapy initiation.Semantic proximity Read ↗

Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin International Normalized Ratio control and bleeding rates.Semantic proximity Read ↗

Integration of genetic, clinical, and INR data to refine warfarin dosing.Semantic proximity Read ↗

Clinical and genetic determinants of warfarin pharmacokinetics and pharmacodynamics during treatment initiation.Semantic proximity Read ↗

An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients.Semantic proximity Read ↗

Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy.Semantic proximity Read ↗

Predicting the warfarin maintenance dose in elderly inpatients at treatment initiation: accuracy of dosing algorithms incorporating or not VKORC1/CYP2C9 genotypes.Semantic proximity Read ↗

Interactive modeling for ongoing utility of pharmacogenetic diagnostic testing: application for warfarin therapy.Semantic proximity Read ↗

A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.